As filed with the Securities and Exchange Commission on August 6, 2012
Registration No. 333-96609
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
MEDTOX SCIENTIFIC, INC.
(Exact name of registrant as specified in its charter)
Delaware | 8071 | 95-3863205 | ||
(State or other jurisdiction of incorporation or Organization) |
(Primary Standard Industrial Classification Number) |
(I.R.S. Employer Identification No.) |
402 West County Road D
St. Paul, MN 55112
(651) 636-7466
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
F. Samuel Eberts III
President and Secretary
MEDTOX Scientific, Inc.
c/o Laboratory Corporation of America Holdings
358 South Main Street
Burlington, NC 27215
(336) 229-1127
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Michael J. Silver
John H. Booher
Hogan Lovells US LLP
875 Third Avenue
New York, NY 10022
(212) 918-3000
Approximate date of commencement of proposed sale to the public: Not applicable.
If any of the securities registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ¨
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the offering. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer | ¨ | Accelerated filer | þ | |||
Non-accelerated filer | ¨ (do not check if a smaller reporting company) | Smaller reporting company | ¨ |
DEREGISTRATION OF UNSOLD SECURITIES
This Post-Effective Amendment No. 1 to Form S-1 relates to the Registration Statement on Form S-1 (333-96609), filed with the Securities and Exchange Commission on July 17, 2002, as amended by Pre-Effective Amendment No. 1 on July 31, 2002, (the Registration Statement) by MEDTOX Scientific, Inc., a Delaware corporation (the Company). The Registration Statement registered the sale of 966,665 shares of the Companys common stock, par value $0.15 per share, to be issued under the Companys Restated Equity Compensation Plan, Qualified Employee Stock Purchase Plan, and the Non-Employee Director Plan (the Compensation Plans).
On July 31, 2012, pursuant to an Agreement and Plan of Merger, dated June 3, 2012, by and among the Company, Laboratory Corporation of America Holdings, a Delaware corporation (LabCorp) and Mercer Acquisition Corp., a Delaware corporation and direct wholly owned subsidiary of LabCorp (Purchaser), Purchaser merged with and into the Company (the Merger), with the Company surviving as a direct wholly owned subsidiary of LabCorp.
As a result of the Merger, the Company ceased to be an independent, publicly-traded company and the Compensation Plans have been terminated. The Company hereby removes from registration the securities registered but unsold under the Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlington, state of North Carolina, on August 6, 2012.
MEDTOX SCIENTIFIC, INC. | ||
By: | /s/ F. Samuel Eberts III | |
Name: | F. Samuel Eberts III | |
Title: | President and Secretary |
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints F. Samuel Eberts III and William B. Hayes, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director and/or officer) to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the date indicated.
Signature | Title | Date | ||
/s/ F. Samuel Eberts III F. Samuel Eberts III |
President, Secretary and Director |
August 6, 2012 | ||
/s/ William B. Hayes William B. Hayes |
Executive Vice President and Treasurer |
August 6, 2012 | ||
/s/ Sandra D. van der Vaart Sandra D. van der Vaart |
Assistant Secretary and Director |
August 6, 2012 |